Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

BACKGROUND: Approximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Melchor, Javier, Garcia-Lacarte, Marcos, Grijalba, Sara C., Arnaiz-Leché, Adrián, Pascual, Marién, Panizo, Carlos, Blanco, Oscar, Segura, Victor, Novo, Francisco J., Valero, Juan Garcia, Pérez-Galán, Patricia, Martinez-Climent, Jose A., Roa, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980368/
https://www.ncbi.nlm.nih.gov/pubmed/36854569
http://dx.doi.org/10.1136/jitc-2022-006113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980368/
https://www.ncbi.nlm.nih.gov/pubmed/36854569
http://dx.doi.org/10.1136/jitc-2022-006113

Ejemplares similares